BCYC

Bicycle Therapeutics Limited

• TipRanks·09/22 13:15

  Bicycle Therapeutics treatment of pancreatic cancer granted orphan designation

• Simply Wall St·08/22 12:10

  Possible Signal As Bicycle Therapeutics Insiders Sell US$523k In Stock

• TipRanks·08/20 21:14

  Bicycle Therapeutics Announces Board and Advisory Resignation

• TipRanks·08/17 15:30

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

• Seeking Alpha·08/04 14:40

  Bicycle: 'Hold' On Zelenectide Deprioritization And Shift To EphA2+ Tumor Targeting

• TipRanks·08/01 01:46

  RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)

• Seeking Alpha·07/31 15:54

  Bicycle a new outperform at Oppenheimer on platform to treat cancer

• TipRanks·07/31 12:00

  Bicycle Therapeutics assumed with an Outperform at Oppenheimer

• TipRanks·07/31 11:45

  Truist Financial Remains a Hold on Bicycle Therapeutics (BCYC)

• NASDAQ·07/31 06:56

  Bicycle Therapeutics Q2 Loss Narrows; Advances Cancer Pipeline

• TipRanks·07/31 06:00

  Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Stryker (SYK) and Bicycle Therapeutics (BCYC)

• Dow Jones·07/30 19:26

  Bicycle Therapeutics Price Target Cut to $14.00/Share From $15.00 by Needham

• Dow Jones·07/30 19:26

  Bicycle Therapeutics Is Maintained at Buy by Needham

• Benzinga·07/30 19:15

  Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

• TipRanks·07/30 16:40

  Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)